GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Total Assets

Mallinckrodt (Mallinckrodt) Total Assets : $3,630 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Total Assets?

Mallinckrodt's Total Assets for the quarter that ended in Mar. 2024 was $3,630 Mil.

During the past 12 months, Mallinckrodt's average Total Assets Growth Rate was -39.80% per year. During the past 3 years, the average Total Assets Growth Rate was -16.30% per year. During the past 5 years, the average Total Assets Growth Rate was -15.00% per year.

During the past 12 years, Mallinckrodt's highest 3-Year average Total Assets Growth Rate was 66.80%. The lowest was -16.30%. And the median was -13.10%.

Total Assets is connected with ROA %. Mallinckrodt's annualized ROA % for the quarter that ended in Mar. 2024 was -6.21%. Total Assets is also linked to Revenue through Asset Turnover. Mallinckrodt's Asset Turnover for the quarter that ended in Mar. 2024 was 0.11.


Mallinckrodt Total Assets Historical Data

The historical data trend for Mallinckrodt's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Total Assets Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,877.30 10,338.90 9,715.40 8,916.30 6,013.80

Mallinckrodt Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,013.80 5,770.80 5,106.90 4,794.80 3,629.60

Mallinckrodt Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Mallinckrodt's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets=Total Equity (A: Dec. 2022 )+Total Liabilities (A: Dec. 2022 )
=1613.7+4400.1
=6,014

Mallinckrodt's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=1091.9+2537.7
=3,630

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mallinckrodt  (OTCPK:MCKPF) Total Assets Explanation

Total Assets is connected with ROA %.

Mallinckrodt's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-261.6/( (4794.8+3629.6)/ 2 )
=-261.6/4212.2
=-6.21 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Mallinckrodt's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=467.8/( (4794.8+3629.6)/ 2 )
=467.8/4212.2
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Mallinckrodt Total Assets Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus